Document is current
Any future updates will be listed below
-
Authors
Di Stefano, Vincenzo
Guaraldi, Pietro
Romano, Angela
Antonini, Giovanni
Barilaro, Alessandro
Briani, Chiara
Burattini, Marco
Cani, Ilaria
Carlini, Giulia
Ceccanti, Marco
Cianci, Vittoria
Cortelli, Pietro
Currò Dossi, Marco
Di Lisi, Daniela
Di Muzio, Antonio
Falzone, Yuri
Filosto, Massimiliano
Gasverde, Sabrina
Gemelli, Chiara
Gentile, Luca
Goglia, Mariangela
Leonardi, Luca
Longhi, Simone
Lotti, Antonio
Manganelli, Fiore
Mazzeo, Anna
Milella, Giammarco
Novo, Giuseppina
Fenu, Silvia
Palumbo, Giovanni
Petrelli, Cristina
Poli, Loris
Pradotto, Luca Guglielmo
Russo, Massimo
Salvalaggio, Alessandro
Sciarrone, Maria Ausilia
Sellitti, Luigi
Tagliapietra, Matteo
Tozza, Stefano
Turri, Mara
Verriello, Lorenzo
Vitali, Francesca
Brighina, Filippo
Luigetti, Marco https://orcid.org/0000-0001-7539-505X
-
Funding
Funding for this research was provided by:
Università Cattolica del Sacro Cuore
- License Information
-
More Information
Article History
Received: 23 November 2024
Revised: 28 January 2025
Accepted: 30 January 2025
First Online: 15 February 2025
Declarations
:
: A.R. received financial grants (honoraria and speaking) from Akcea, and travel grants to attend scientific meetings from Akcea, Alnylam, Pfizer, and Csl Behring. A.B. received financial grants (honoraria and speaking) from Alnylam. C.B. received speaker and consulting honoraria from Alnylam, Ionis, and Pfizer, and travel grants from Kedrion, Alnylam, and CSL Behring. S.F. acknowledges financial support from Alnylam and Pfizer for participation in national and international meetings. C.G. received financial grants (speaking) from Italfarmaco, and travel grants from Biogen for participation in national meetings. L.G. received financial grants (honoraria and speaking) from Akcea, Alnylam, and Pfizer, and travel grants from Alnylam and CSL Behring. L.L received financial grants (honoraria and speaking) from Alnylam, and travel grants to attend scientific meetings from Akcea, SOBI, Alnylam. A.S. received a travel grant to attend scientific meetings from Alnylam. S.T. received personal fees for scientific events from Alnylam Pharmaceuticals, Amicus Therapeutics and Takeda Pharmaceutical Co, travel grants to attend scientific meetings from Akcea Therapeutics. M.L. received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and Pfizer, and travel grants from Ackea, Alnylam, Sobi, Pfizer, Kedrion, and Grifols. Other authors have no conflict of interest to declare.
: The study was approved by the Ethical Committee of Palermo on 26th June 2023 (V n.6/2023), and it was conducted in conformity with the Declaration of Helsinki principles. Written informed consent was obtained from each enrolled individual before inclusion.
